Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: The Baltimore Longitudinal Study of Aging

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 4, 2012, Pages 1375-1382

  Semba, Richard D ^a   Sun, Kai ^a   Egan, Josephine M ^b   Crasto, Candace ^a   Carlson, Olga D ^b   Ferrucci, Luigi ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE; INSULIN;

ADULT; AGED; AGING; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; COMMUNITY LIVING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISTRICT OF COLUMBIA; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; LONGITUDINAL STUDIES; MALE; MARYLAND; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 84859531060     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2823     Document Type: Article

References (27)

1. Kralisch S, Fasshauer M 2011 Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease. Curr Opin Clin Nutr Metab Care 14:354-359
2. Kliewer SA, Mangelsdorf DJ 2010 Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 91(Suppl):254S-257S
3. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, Eliseenkova AV, Mohammadi M, Kuro-o M 2007 BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 104:7432-7437 (Pubitemid 47185923)
4. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB 2005 FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627-1635 (Pubitemid 40814671)
5. Chau MD, Gao J, Yang Q, Wu Z, Gromada J 2010 Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1α pathway. Proc Natl Acad Sci USA 107: 12553-12558
6. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ 2007 The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774-781 (Pubitemid 46143178)
7. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, Xu A 2008 Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246-1253
8. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, Feng W, Li X 2010 Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 5:e15534
9. Mashili FL, Austin RL, Deshmukh AS, Fritz T, Caidahl K, Bergdahl K, Zierath JR, Chibalin AV, Moller DE, Kharitonenkov A, Krook A 2011 Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes mellitus. Diabetes Metab Res Rev 27:286-297
10. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, Matoulek M, Dostalova I, Humenanska V, Haluzik M 2009 Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf)71:369-375
11. Chen C, Cheung BM, Tso AW, Wang Y, Law LS, Ong KL, Wat NM, Xu A, Lam KS 2011 High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population- based prospective study in Chinese subjects. Diabetes Care 34:2113-2115
12. Shock NW, Greulich RC, Andres RA, Arenberg D, Casta PT, Lakatta EG, Tobin JP 1984 Normal human aging: the Baltimore Longitudinal Study of Aging. Washington, DC: U.S. Government Printing Office
13. World Health Organization 1995 Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization
14. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P 2003 Follow-up report on the diagnosis of diabetes mellitus. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26:3160-3136
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
16. Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470 (Pubitemid 29418240)
17. Kalyani RR, Metter EJ, Ramachandran R, Chia CW, Saudek CD, Ferrucci L 2012 Glucose and insulin measurements from the oral glucose tolerance test and relationship to muscle mass. J Gerontol A Biol Sci Med Sci 67:74-81
18. Warnick G, Benderson J, Albers JJ 1982 Dextran sulfate-Mg2+ precipitation procedure for quantification of high-density-lipoprotein cholesterol. Clin Chem 28:1379-1388 (Pubitemid 12125081)
19. Friedewald WT, Levy RI, Frederickson DS 1972 Estimation of the concentration of low-density-lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D 1999 A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130: 461-470 (Pubitemid 29135798)
21. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, De- Fronzo RA, Tripathy D 2009 Circulating fibroblast growth factor- 21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32:1542-1546
22. Gälman C, Lundåsen T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, Dahlin M, Amark P, Angelin B, Rudling M 2008 The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man. Cell Metab 8:169-174
23. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, Jia W 2009 Serum fibroblast growth factor 21 is associated with adverse lipid profiles and γ-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 94:2151-2156
24. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E 2010 Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59:2781-2789
25. Andersen B, Beck-Nielsen H, Højlund K 2011 Plasma FGF21 displays a circadian rhythm during a 72 hour fast in healthy female volunteers. Clin Endocrinol (Oxf) 75:514-519
26. Stein S, Bachmann A, Lössner U, Kratzsch J, Blüher M, Stumvoll M, Fasshauer M 2009 Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 32:126-128
27. Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, Mohammadi M, Finck BN, Mangelsdorf DJ, Kliewer SA, Burgess SC 2009 FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 106:10853-10858